Zacks Investment Research cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

Several other equities research analysts also recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the company an overweight rating in a research report on Monday, June 4th. SunTrust Banks started coverage on shares of Deciphera Pharmaceuticals in a research report on Thursday, July 5th. They issued a buy rating for the company. BidaskClub downgraded shares of Deciphera Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, April 26th. B. Riley reduced their price target on shares of Deciphera Pharmaceuticals from $52.00 to $43.00 and set a buy rating for the company in a research report on Wednesday, May 9th. Finally, JMP Securities upped their price target on shares of Deciphera Pharmaceuticals to $65.00 and gave the company an outperform rating in a research report on Tuesday, June 19th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of $50.13.

Shares of NASDAQ:DCPH traded down $1.43 during mid-day trading on Tuesday, hitting $34.09. The stock had a trading volume of 38,531 shares, compared to its average volume of 199,137. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44. The company has a market cap of $1.34 billion and a PE ratio of -11.40. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. equities analysts predict that Deciphera Pharmaceuticals will post -2.61 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC lifted its position in Deciphera Pharmaceuticals by 30.8% in the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after buying an additional 472,800 shares in the last quarter. Redmile Group LLC lifted its position in Deciphera Pharmaceuticals by 79.9% in the 2nd quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after buying an additional 655,800 shares in the last quarter. FMR LLC lifted its position in Deciphera Pharmaceuticals by 33.5% in the 2nd quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after buying an additional 296,571 shares in the last quarter. Emerald Advisers Inc. PA lifted its position in Deciphera Pharmaceuticals by 23.0% in the 2nd quarter. Emerald Advisers Inc. PA now owns 592,224 shares of the company’s stock worth $23,304,000 after buying an additional 110,785 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Deciphera Pharmaceuticals by 18.2% in the 2nd quarter. BlackRock Inc. now owns 591,064 shares of the company’s stock worth $23,258,000 after buying an additional 91,185 shares in the last quarter. Institutional investors own 42.63% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Read More: Understanding Analyst Ratings

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.